Format

Send to

Choose Destination
Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):325-38. doi: 10.1016/j.beem.2013.12.001. Epub 2013 Dec 18.

Lipids and lipid management in diabetes.

Author information

1
Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
2
University of Michigan Medical School, Ann Arbor, MI, USA.
3
Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA. Electronic address: rpbusui@umich.edu.

Abstract

Cardiovascular disease is more prevalent in type 1 and type 2 diabetes, and continues to be the leading cause of death among adults with diabetes. Although atherosclerotic vascular disease has a multi-factorial etiology, disorders of lipid metabolism play a central role. The coexistence of diabetes with other risk factors, in particular with dyslipidemia, further increases cardiovascular disease risk. A characteristic pattern, termed diabetic dyslipidemia, consists of increased levels of triglycerides, low levels of high density lipoprotein cholesterol, and postprandial lipemia, and is mostly seen in patients with type 2 diabetes or metabolic syndrome. This review summarizes the trends in the prevalence of lipid disorders in diabetes, advances in the mechanisms contributing to diabetic dyslipidemia, and current evidence regarding appropriate therapeutic recommendations.

KEYWORDS:

cardiovascular disease; dyslipidemia; fibrates; lifestyle intervention; statins; type 1 diabetes; type 2 diabetes

PMID:
24840262
DOI:
10.1016/j.beem.2013.12.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center